Over 85 warning letters have been issued in two enforcement waves, primarily targeting two kinds of marketing claims: implying compounded products are equivalent to FDA-approved drugs, and misrepresenting which entity is doing the actual compounding
Not for consumption
The majority of patients across all groups those currently on a GLP-1, thinking of it, or who used to take one said "yes." Among those who used to take a GLP-1, 42% said they gained "some" weight back after stopping treatment
Some are prescribed for type 2 diabetes, some are prescribed for weight loss, and some are compared for both their metabolic and cardiovascular effects
Patients may experience more pronounced gastrointestinal symptoms during titration, which can influence their willingness to continue treatment
Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor